Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today...
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference, April 15, 2026, at 10:15 a.m....
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Compensation Committee of KalVista’s Board of Directors granted five newly-hired employees inducement options to purchase an aggregate...
Interim data show sebetralstat enables early, effective treatment of hereditary angioedema (HAE) attacks in children with favorable safety and tolerability
$49.1 million global net product revenue of EKTERLY ® (sebetralstat) for the eight months ended December 31, 2025 1,702 patient start forms...
$49.1 million global net product revenue of EKTERLY ® (sebetralstat) for the eight months ended December 31, 2025 1,702 patient start forms...
New interim data from the KONFIDENT-KID trial evaluating sebetralstat in children aged 2-11 accepted for late-breaking oral presentation
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) will host a conference call and webcast on Wednesday, March 25, 2026, at 8:30 a.m. ET to review the Company’s eight months fiscal year 2025 financial results...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Compensation Committee of KalVista’s Board of Directors granted one newly-hired employee inducement options to purchase an aggregate...